      Document 0177
 DOCN  DRG0177
 UNIQUE IDENTIFIER        DRG-0070
 NAME OF SUBSTANCE        Keyhole-Limpet Hemocyanin [Merck Index 1989]
 SYNONYMS                 KLH [Merck Index 1989]
 SYNONYMS                 Keyhole-limpet haemacyanin [MeSH]
 SYNONYMS                 Keyhole-limpet hemacyanin [MeSH]
 SYNONYMS                 Immunocyanine [MeSH]
 PROTOCOL ID NUMBERS      NIAID 87 I-114
 SECONDARY SOURCE ID      DRG
 DISEASES STUDIED/TREATED Used as a control agent in immune response
                          studies of AIDS patients [NIAID 87 I-114]
 CLASSIFICATION CODE      Immunomodulator [MeSH]
 OTHER MAJOR USES         Immunological control agent; baseline immune
                          response in clinical research [NIAID 87
                          I-114]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: Non-heme, oxygen-carrying
                          copper protein [Merck Index 1989]
 CHEMICAL/PHYSICAL DATA   MOLECULAR WEIGHT: Ranges from 4.5 x 10(5) to
                          1.3 x 10(7) [Merck Index 1989]
 CHEMICAL/PHYSICAL DATA   PHYSICAL DESCRIPTION: Oxygenated form
                          (oxyhemocyanin) is blue, while deoxygenated
                          form (deoxyhemocyanin) is colorless [Merck
                          Index 1989]
 REFERENCES               Weissman DN, Bice DE, Crowell RE, Schuyler
                          MR. Intrapulmonary antigen deposition in the
                          human lung: local responses. Am J Respir Cell
                          Mol Biol. 1994 Nov;11(5):607-14.
 REFERENCES               Goldstein AL, Sarin PS, Markham R, Kahn J,
                          Heseltine P, Gazzard B, Youle M. Cytotoxic
                          and humoral immune responses to HIV-1 p17
                          synthetic peptide HGP-30 in human volunteers.
                          Int Conf AIDS. 1993 Jun 6-11;9(1):45-50.
 REFERENCES               Whittle H, Egboga A, Todd J, Morgan G, Rolfe
                          M, Sabally S, Wilkins A, Corrah T.
                          Inmmunological responsis of Gambians in
                          relation to clincal stage of HIV-2 disease.
                          Clin Exp Immunol. 1993 Jul;93(1):45-50.
 REFERENCES               Kahn JO, Stites DP, Scillian J, Murcar N,
                          Stryker R, Volberding PA, Naylor PH,
                          Goldstein AL, Sarin PS, Simmon VF, et al. A
                          phase I study of HGP-30, a 30 amino acid
                          subunit of the human immunodeficiency virus
                          (HIV) p17 synthetic peptide analogue sub-unit
                          vaccine in seronegative subjects. AIDS Res
                          Hum Retroviruses. 1992 Aug;8(8):1321-5.
 REFERENCES               Okuda K, Inami S, Kaneko T. Strong
                          synergistic effects of polyvalent vaccine for
                          human immunodeficiency virus (HIV-1)
                          infection. Int Conf AIDS. 1992 Jul
                          19-24;8(2):A73 (abstract no. PoA 2425).
 REFERENCES               Naylor PH, Sztein MB, Wada S, Maurer S,
                          Holterman D, Kirkley JE, Naylor CW, Zook BC,
                          Hitzelberg RA, Gibbs CJ Jr, et al.
                          Preclinical and clinical studies on
                          immunogenicity and safety of the HIV-1
                          p17-based synthetic peptide AIDS
                          vaccine--HGP-30-KLH. Int J Immunopharmacol.
                          1991;13 Suppl 1:117-27.
 REFERENCES               Stambuk D, Vallerich M, Youle M, Rios A,
                          Naylor P, Sarin P, Goldstein A, Gazzard B.
                          Phase I study of HGP-30, an HIV p17 synthetic
                          peptide analogue sub-unit vaccine in humans.
                          Int Conf AIDS. 1990 Jun 20-23;6(2):327
                          (abstract no. 1054).
 REFERENCES               Samson J, Charest J, Paquet C, Lapointe N.
                          HIV activation by cofactors: P-24 antigenemia
                          after injections of soluble antigens in
                          children with AIDS. Int Conf AIDS. 1989 Jun
                          4-9;5:312 (abstract no. T.B.P.151).
 ENTRY MONTH              8910
 LAST REVISION DATE       950927
 

SOURCE: National Library of Medicine, Bethesda, MD.  Distributed by AEGIS.
